



Company	Telix Pharmaceuticals
Code	TLX
Meeting	AGM
Date	12th May 2020
Venue	55 Flemington Rd, North Melbourne/Virtual
Monitor	Alan Hardcastle (proxy collector)

Number attendees at meeting	Virtual/unknown
Number of holdings represented by ASA	1
Value of proxies	\$1,500
Number of shares represented by ASA	1,000
Market capitalisation	\$370m
Were proxies voted?	Yes, on a poll
Pre AGM Meeting?	No

Transitioning from diagnostics revenue base to therapeutics company

Financial report and Directors' reports are available at: <https://telixpharma.com/investors/#asx>

Telix is less than three years old as an ASX-listed company and, while domiciled in Australia, its business is truly global. This year was the ASA's first 'involvement' with the Company.

The Monitor posed questions (via the Company Secretary) to the Board about one week before the AGM, complemented, for the Board's information, an attached 'ASA Voting Guidelines - Summary'. The day before the AGM the Monitor was sent, by Link Market Services, the ASA's Holder Voting by Proxy Form. Shareholders were also sent a 6-page instruction booklet on how to participate at the virtual AGM.

The Virtual AGM went very well in technical terms apart from when this Monitor's 'connection' was terminated just before the final resolution. According to Link, there had been no other reported glitches. The Link Virtual Meeting software allowed shareholders to pose questions during the meeting as well as vote on resolutions. It was a very easy site to navigate. On one 'home page' Investors could view a picture of the person speaking; slides appropriate to the speech; links for voting and posing questions; and downloads of ASX AGM related docs.

The Virtual AGM was conducted from the Company's Melbourne head office with all Non-Executive Directors 'present' on-line with an apology from Germany-based Executive Director Andreas Kruege.

Chair Kevin McCann and Chief Executive Officer Christian Behrenbruch addressed the meeting, which lasted for about 50 minutes.

The CEO's presentation emphasised that Telix is not simply a diagnostic imaging company, as perceived by the market, but in reality a Company which is transitioning to being a therapeutics company. Telix has more than 30 clinical trial sites globally with its own operations in Japan, Europe and the US. While Covid-19 has slowed activity on these sites, it is expected that from 1st September it will be reignited.

As this Company develops a sustainable revenue stream, a Remuneration Scheme using performance-based metrics will be instituted.

There were only two questions posed to the meeting, both by the ASA Monitor. The Chair emphasised that the CEO's external commitments - NED of two small cap publicly listed bio tech companies - were ceasing. He also explained Telix does have a Diversity policy, which targets 40/50% females at Board level and in the 'high performance group'.

The ASA voted in favour of all Resolutions, all of which were passed unanimously.